A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

NCT00617890 ·Status: TERMINATED ·Phase: PHASE2

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00387894 ·Status: TERMINATED ·Phase: PHASE2

Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery

NCT00098579 ·Status: COMPLETED ·Phase: PHASE1

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

NCT00281866 ·Status: COMPLETED ·Phase: PHASE2

Tivozanib + Gemcitabine in Metastatic RCC

NCT01834183 ·Status: WITHDRAWN ·Phase: PHASE2

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

NCT00245102 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

NCT06053658 ·Status: RECRUITING ·Phase: PHASE2

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

NCT02097238 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700 ·Status: TERMINATED ·Phase: PHASE2

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

NCT00003292 ·Status: TERMINATED ·Phase: PHASE2

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

NCT01248858 ·Status: TERMINATED ·Phase: PHASE1

Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

NCT04066595 ·Status: TERMINATED ·Phase: PHASE2

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

NCT00810394 ·Status: COMPLETED ·Phase: PHASE2

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

NCT06667544 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

NCT01061606 ·Status: TERMINATED ·Phase: PHASE2

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

NCT00410462 ·Status: UNKNOWN ·Phase: PHASE2

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

NCT00077285 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma

NCT00002259 ·Status: COMPLETED ·Phase: PHASE2

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

NCT05415072 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

NCT01639508 ·Status: RECRUITING ·Phase: PHASE2

Dolastatin 10 in Treating Patients With Advanced Kidney Cancer

NCT00003914 ·Status: COMPLETED ·Phase: PHASE2

Advanced or Recurrent Solid Tumors Treated With SHetA2

NCT04928508 ·Status: RECRUITING ·Phase: PHASE1

Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies

NCT00666081 ·Status: WITHDRAWN ·Phase: PHASE1

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

NCT00066612 ·Status: COMPLETED ·Phase: PHASE2